CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC

9 months ago 51

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

1. Homepage
2. Lung Cancer
3. CHMP Recommends Perioperative Durvalumab Regimen in Resectable NSCLC